Business
Anergis and Mymetics Start Research Collaboration Project on the use of Virosomes for Ultra-Fast Allergy Immunotherapy
Anergis and Mymetics Start Research Collaboration Project on the use of Virosomes for Ultra-Fast Allergy Immunotherapy.
About this update from Mymetics Corp.
[{"type":"text","content":"EPALINGES, SWITZERLAND / ACCESSWIRE / April 23, 2018 / Mymetics Corporation (OTCQB:MYMX), a pioneer and leader in the research and development of virosome-based vaccines, and Anergis SA, a company developing Contiguous Overlapping Peptides (COPs) for ultra-fast allergy immunotherapy, announced today that Mymetics SA, the Swiss subsidiary of Mymetics Corporation and Anergis SA have entered into a Research Collaboration project.The pre-clinical study program will evaluate the immunogenicity profile of the Anergis peptides designed to treat birch allergy (the Bet v1 COPs) when presented on Mymetics' proprietary virosomes, with or without undisclosed TLR ligands or other adjuvants, and will compare the results to Anergis' AllerT product combination (Bet v1 COPs with aluminum hydroxide).The research collaboration will start now and the results are expected by Q1 2019. If this project is successful, Anergis will have the option to enter into an exclusive license agreement for the use of virosomes in allergy.\"We are very excited to start this initial research project with Anergis, a leading company in ultra-fast allergy immunotherapy\" said Ronald Kempers, CEO of Mymetics. \"We look forward to show that our proprietary virosome technology and vaccine expertise can make a valuable difference in improving the effectiveness of treating allergies.\"\"On the basis of the extensive clinical experience available with virosomes and with Anergis COPs against birch allergy, we are convinced that their combination represents a highly attractive opportunity to develop safe and efficacious ultra-fast COP allergy vaccines\" commented Vincent Charlon, CEO of Anergis.About MymeticsMymetics Corporation (OTCQB:MYMX) is a Swiss based biotechnology company, with a research lab in the Netherlands, focused on the development of next-generation preventative vaccines for infectious and life disabling diseases. It currently has five vaccines in its pipeline: HIV-1/AIDS, intra-nasal Influenza, Malaria, Chikungunya, Herpes Simplex Virus and the RSV vaccine. HIV, malaria and intra-nasal influenza vaccines have successfully finished Phase 1 clinical trials, while the others are in the pre-clinical phase.Mymetics' core technology and expertise are in the use of virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane protein...